Scarica l'app Stockscreener
3.17
5.23%
-0.175
Precedente Chiudi:
$3.345
Aprire:
$3.16
Volume 24 ore:
41,347
Relative Volume:
1.74
Capitalizzazione di mercato:
$17.90M
Reddito:
-
Utile/perdita netta:
$-16.35M
Rapporto P/E:
-1.0393
EPS:
-3.05
Flusso di cassa netto:
$-11.88M
1 W Prestazione:
-8.65%
1M Prestazione:
+3.26%
6M Prestazione:
-25.41%
1 anno Prestazione:
-36.22%
Intervallo 1D:
$3.16
$3.409
Intervallo di 1 settimana:
$3.00
$3.57
Portata 52W:
$2.96
$11.79
Lipocine Inc Stock (LPCN) Company Profile
Nome
Lipocine Inc
Settore
Industria
Telefono
801 994 7383
Indirizzo
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Confronta LPCN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
3.17 | 17.90M | 0 | -16.35M | -11.88M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-06-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2018-01-12 | Reiterato | H.C. Wainwright | Buy |
| 2018-01-11 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2017-12-08 | Ripresa | H.C. Wainwright | Buy |
| 2016-10-07 | Iniziato | H.C. Wainwright | Buy |
| 2015-07-22 | Iniziato | ROTH Capital | Buy |
| 2015-06-23 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Lipocine Inc Borsa (LPCN) Ultime notizie
Lipocine (NASDAQ:LPCN) Coverage Initiated by Analysts at StockNews.com - Defense World
Lipocine’s Phase III trial of LPCN 1154 to begin for postpartum depression - Yahoo Finance
Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154 - MarketScreener
Revolutionary At-Home Postpartum Depression Drug Enters Final Testing Phase - Stock Titan
StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN) - Defense World
Testosterone, TRAVERSE, And A Label Change 15 Years In The Making - News & Insights
Lipozem Reviews (2025): Consumer Reports on Lipozem Weight Loss Formula - GlobeNewswire Inc.
Lipocine Announces Financial Results for the Full Year Ended December 31, 2024 - Quantisnow
Lipocine Turns Profitable: How $11.2M in Licensing Deals Transformed 2024 Results - StockTitan
Lipocine to change FDA labeling for testosterone products -March 12, 2025 at 09:59 am EDT - Marketscreener.com
Lipocine Announces FDA Labeling Changes for Testosterone Products - Citizentribune
Lipocine announces FDA labeling changes for testosterone products - TipRanks
FDA Lifts Critical Cardiovascular Warning for Testosterone Treatments: Major Win for Lipocine - StockTitan
Lipocine (NASDAQ:LPCN) Coverage Initiated at StockNews.com - Defense World
LPCN stock touches 52-week low at $2.92 amid market challenges By Investing.com - Investing.com South Africa
LPCN stock touches 52-week low at $2.92 amid market challenges - Investing.com UK
Lipocine Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024 - Marketscreener.com
Lipocine (LPCN) Expected to Announce Earnings on Thursday - Defense World
Lipocine (NASDAQ:LPCN) Now Covered by StockNews.com - Defense World
Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com - Armenian Reporter
Lipocine Updates Corporate Presentation in Recent 8-K Filing - Defense World
Lipocine (NASDAQ:LPCN) Receives Updated Regulatory Guidance for LPCN 1154 - Defense World
Lipocine plans phase 3 study for postpartum depression drug - MSN
Lipocine Inc. Receives Updated Regulatory Guidance on LPCN 1154 -February 06, 2025 at 09:30 am EST - Marketscreener.com
Lipocine plans phase 3 study for postpartum depression drug By Investing.com - Investing.com South Africa
Lipocine Receives Updated Regulatory Guidance on LPCN 1154 - The Herald Journal
Lipocine (NASDAQ:LPCN) Earns Hold Rating from Analysts at StockNews.com - Defense World
Postpartum Depression Market Expected to rise, 2034 | Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, expected to drive market - Barchart
Lipocine Updates Corporate Presentation, Files 8-K with SEC - Defense World
(LPCN) On The My Stocks Page - Stock Traders Daily
StockNews.com Begins Coverage on Lipocine (NASDAQ:LPCN) - Defense World
FDA Grants Fast Track Designation to Lipocine (NASDAQ:LPCN) for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis - Defense World
Lipocine Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits - Quantisnow
FDA fast tracks Lipocine's sarcopenia treatment - Investing.com
FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis - PR Newswire
FDA Grants Fast Track Designation to LPCN 1148 as Treatment for Sarcopenia - Contract Pharma
Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference - The Eastern Progress Online
Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session - The Eastern Progress Online
Where are the Opportunities in (LPCN) - Stock Traders Daily
Lipocine Inc Azioni (LPCN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):